Interview with Martin Nelzow, CEO, Boehringer Ingelheim Brazil
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
Address: Rochaverá Corporate Towers. Av. Nações Unidas, 14.171 – Torre Marble – 18º andar – São Paulo – SP. CEP: 04794-000
Tel: (11) 4949-4700
Web: http://www.boehringer-ingelheim.com.br/principal.asp
The Boehringer Ingelheim group is one of the top 20 pharmaceutical companies in the world. Headquartered in Ingelheim, Germany, operates globally with 138 affiliates in 47 countries and 41,300 employees. Since its founding in 1885, this family business is committed to researching, developing and marketing novel products of high therapeutic value for human and veterinary medicine.
Present in Brazil since 1956, headquartered in Sao Paulo and factory in Itapecerica da Serra (SP), the company employs approximately 1,000 employees and sells products with brands like Anador ®, Bisolvon ®, Buscopan ®, Dulcolax ®, and Mucosolvan ® ® Pharmaton , and several prescription products, with an outstanding performance in the areas respiratory, cardiovascular, Parkinson’s and others.
Located in Itapecerica da Serra, São Paulo, the Brazilian plant has excellence in the manufacture of medicines and is one of the largest and most modern of the group in the world, accounting for the 3rd largest production volume, representing 10% of the company’s global . Through its Industrial Business Area, the plant of Boehringer Ingelheim in Brazil also produces products for other laboratories.
Since 1998, Boehringer Ingelheim has been designated by the Great Place to Work Institute as one of the 100 best companies to work in Brazil. In total, there have been nine nominations, eight of them consecutive. Since 2004 the company has also been designated by the Great Place to Work as one of the best companies to work in Latin America.
Anador ®, Bisolvon ®, Buscopan ®, Dulcolax ®, and Mucosolvan ® ® Pharmaton
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
The latest pharma news from Brazil, including Daiichi Sankyo’s new plant; Bristol Myers Squibb’s re-entry into Brazil’s cardiology market; the Anvisa approval of HIV prevention drug, cabotegravir; Merck’s gamble on…
A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences…
Having spent 25 years in the rare disease arena, Maria Gabriella Pittis now finds herself at the forefront of a different field, spearheading the launch of Takeda’s dengue vaccine across…
As the COVID-19 pandemic showed, vaccines are humanity’s best weapon in the fight against infectious diseases. Nowhere is this more evident than Latin America, where specific climatic, geographic, and social…
Henrique Tada of ALANAC, the association that brings together Brazil’s domestic pharma companies, comments on the evolution of the Brazilian generics, biosimilars, and value-added medicines markets, local laboratories’ internationalisation efforts,…
In a wide-ranging interview, AbbVie’s Flavio Devoto outlines some of the key access challenges and opportunities in the diverse Latin American pharma market, his approach to being a transformational leader…
The latest from Brazilian Pharma, including the controversial proposal to transform Brazil’s regulatory agency, ANVISA; Ease Labs’s canabidiol approval, Biolab’s international expansion ambitions and Eurofarma’s multiple myeloma deal. ANVISA’s…
Sarah Aiosa oversees the entire Latin America region for MSD, where the global giant is looking to build on its 100-year legacy by better addressing the continent’s health inequities and…
Latin America is a rapidly growing market for the global medtech industry, offering significant opportunities. With a population of over 650 million people, the region boasts a large and growing…
Guilherme Marques, president of Siemens Healthineers LatAm, discusses the health tech giant’s regional strategy, covering how the firm rides out the region’s economic and political storms, its participation in disease…
Latin America is a crucial region for medtech market leader Medtronic. Home to 20,000 of the company’s 95,000+ global workforce, 12 manufacturing plants, and ten commercial organisations, Medtronic LatAm grew…
In 2019 the pharma industry financed some 700 clinical studies in Latin America with investments of more than USD one billion and according to FIFARMA, the leading association of innovators…
See our Cookie Privacy Policy Here
